3023 Mayo Clinic Patients With Myeloproliferative Neoplasms: Risk-Stratified Comparison of Survival and Outcomes Data Among Disease Subgroups
2019/02/26 by Natasha Szuber, Mythri Mudireddy, Maura Nicolosi +18 · 28 citations
Medicine · #Myeloproliferative Neoplasms: Diagnosis and Treatment #Acute Myeloid Leukemia Research #Multiple Myeloma Research and Treatments
paper · doi:10.1016/j.mayocp.2018.08.022
Citations
Cited by
- Polycythemia vera: 2024 update on diagnosis, risk‐stratification, and management
- Primary myelofibrosis: 2023 update on diagnosis, risk‐stratification, and management
- Essential Thrombocythemia
- Updates in the management of polycythemia vera and essential thrombocythemia. [europepmc]
- Bioinformatics Analysis of Key Genes and Pathways Associated with Thrombosis in Essential Thrombocythemia. [europepmc]
- Beyond Ruxolitinib: Fedratinib and Other Emergent Treatment Options for Myelofibrosis. [europepmc]
- JAK2 exon 12 mutations in cases with JAK2V617F-negative polycythemia vera and primary myelofibrosis. [europepmc]
- Interferon alpha therapy in essential thrombocythemia and polycythemia vera-a systematic review and meta-analysis. [europepmc]
- Prognostic value of ASXL1 mutations in patients with primary myelofibrosis and its relationship with clinical features: a meta-analysis. [europepmc]
- Venetoclax with azacitidine or decitabine in blast-phase myeloproliferative neoplasm: A multicenter series of 32 consecutive cases. [europepmc]
- Accelerated Phase of Myeloproliferative Neoplasms. [europepmc]
- The Epidemiology of Myeloproliferative Neoplasms in New Zealand between 2010 and 2017: Insights from the New Zealand Cancer Registry. [europepmc]
- Polycythemia vera: historical oversights, diagnostic details, and therapeutic views. [europepmc]
- Real-world survival of US patients with intermediate- to high-risk myelofibrosis: impact of ruxolitinib approval. [europepmc]
- The Classification of Myeloproliferative Neoplasms: Rationale, Historical Background and Future Perspectives with Focus on Unclassifiable Cases. [europepmc]
- Improved survival of patients with myelofibrosis in the last decade: Single-center experience. [europepmc]
- Cytogenetic abnormalities in essential thrombocythemia: Clinical and molecular correlates and prognostic relevance in 809 informative cases. [europepmc]
- Therapeutic activity of GARP:TGF-β1 blockade in murine primary myelofibrosis. [europepmc]
- TET2 Mutation May Be More Valuable in Predicting Thrombosis in ET Patients Compared to PV Patients: A Preliminary Report. [europepmc]
- Molecular prognostication in Ph-negative MPNs in 2022. [europepmc]
- International Consensus Classification of myeloid and lymphoid neoplasms: myeloproliferative neoplasms. [europepmc]
- Hepcidin mimetics in polycythemia vera: resolving the irony of iron deficiency and erythrocytosis. [europepmc]
- Momelotinib (JAK1/JAK2/ACVR1 inhibitor): mechanism of action, clinical trial reports, and therapeutic prospects beyond myelofibrosis. [europepmc]
- Blast phase myeloproliferative neoplasm: contemporary review and 2024 treatment algorithm. [europepmc]
- The impact of thrombosis on probabilities of death and disease progression in polycythemia vera: a multistate transition analysis of 1,545 patients. [europepmc]
- One thousand patients with essential thrombocythemia: the Mayo Clinic experience. [europepmc]
- A randomized, double-blind, placebo-controlled phase 3 study to assess efficacy and safety of ropeginterferon alfa-2b in patients with early/lower-risk primary myelofibrosis. [europepmc]
- Evolution of WHO diagnostic criteria in "Classical Myeloproliferative Neoplasms" compared with the International Consensus Classification. [europepmc]